Therapeutic Areas

Monthly, higher doses of novel therapy SRP-5051 (vesleteplirsen) found to produce substantially greater increases in dystrophin and exon skipping compared to the lower weekly dose.

Tremfya achieved the co-primary endpoints of Scalp-Specific Investigator Global Assessment score of 0/1 and Psoriasis Scalp Severity Index 90 response at week 16 in the trial.

Data from prior Phase II study showed signs of pridopidine slowing disease progression in patients with amyotrophic lateral sclerosis.

A discussion of where cell and gene therapies are currently doing, what's on the horizon, personalization, and much more.

Utility Therapeutics’ pivmecillinam is an oral antibiotic for the treatment of uncomplicated urinary tract infections.

With $13 million grant, Vanderbilt University Medical Center will lead the new multisite trial.

A pair of clinical trials show the rapid and reliable efficacy of Zoryve in treating atopic dermatitis and seborrheic dermatitis.

Data from the Phase III LIBERTY-AD-HAFT trial show 40% of patients with atopic dermatitis with uncontrolled moderate-to-severe hand and/or foot involvement who were administered Dupixent achieved clear or almost clear skin on their hands and feet.

Clinical study identifies combination of 11 proteins that can predict long-term disability in patients with multiple sclerosis.

AbbVie will advance the clinical program for the investigational, dual-variable-domain IL 1α/1β antagonist lutikizumab to Phase III for the treatment of adults with moderate to severe hidradenitis suppurativa who previously failed anti-TNF therapy.

Phase III ASC4FIRST show Scemblix (asciminib) plus investigators’ choice of tyrosine kinase inhibitor produced a statistically significant response in patients newly diagnosed with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.

The use of modeling and biosimulation can help predict potential outcomes and improve confidence in therapeutic candidates for Alzheimer disease.

Webinar Date/Time: Tuesday, February 6th, 2024 at 11am EST | 8am PST | 4pm GMT | 5pm CET

In an interview with ACT editor, Andy Studna, Hesterlee, Chief Research Officer at the Muscular Dystrophy Association discusses a new therapy for Duchenne Muscular Dystrophy, Vamorolone, and what sets it apart from other therapies in the market.

A planned analysis of the KEYNOTE-942/mRNA-4157-P201 clinical trial found that at a median follow-up of approximately three years, adjuvant treatment with Moderna’s mRNA-4157 (V940) in combination with Keytruda continued to show a clinically meaningful improvement in recurrence-free survival in patients with resected high-risk melanoma.

PrEPVacc halts study of experimental HIV vaccine regimens and a new form of oral pre-exposure prophylaxis.

DREAMM-7 was a Phase 3, multicenter, open-label, randomized trial analyzing the efficacy and safety of Blenrep plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously administered at least one prior line of treatment.

Education and equitable access are key to unlocking its full potential in the present and future.

Rexulti was found to be a well-tolerated treatment for the debilitating symptoms of agitation associated with dementia due to Alzheimer’s disease.

Studies with Zenith-CKD showed significant albuminuria reduction.

BI 690517 is a novel, potent, highly selective aldosterone synthase inhibitor that reduces the progression of kidney damage and lowers the risk of cardiovascular events in patients with chronic kidney disease.

The approval of pembrolizumab (Keytruda; Merck) combined with gemcitabine and cisplatin for the treatment locally advanced unresectable or metastatic biliary tract cancer is the sixth sixth indication for the anti-PD-1 therapy for gastrointestinal cancers.

Bingham discusses the logistical challenges associated with coordinating patient involvement in rare disease clinical trials.

Exploring the implications of FDA’s renewed focus and commitment to expand the use of accelerated approval for gene therapy products.

New protocols, remote patient monitoring, and improved standards of care among ways industry can take next steps in CAR T-cell research.

Webinar Date/Time: Wed, Sep 20, 2023 10:00 AM EDT

Clinical trials in this area reflect new science, and corresponding challenges in their execution.

Webinar Date/Time: Thursday, September 7th, 2023 at 10am EDT | 7am PDT | 3pm BST | 4pm CEST

In this Q&A, David Esposito, CEO of ONL Therapeutics provides a glimpse into the company's mission, challenges, and strategies associated with clinical trials.

In support of the recent ARPA-H NITRO OA Cure Moonshot, the online resources identifies major OA treatment trials and allows patients to sign up.